NeonMind Developing Music Playlist for Psychedelic Therapy Sessions
1/3
NeonMind Developing Music Playlist for Psychedelic Therapy Sessions
Vancouver, British Columbia--(Newsfile Corp. - April 6, 2021) - NeonMind Biosciences Inc. (CSE: NEON)
(FSE: 6UF) (OTC PINK: NMDBF) ("NeonMind"), is pleased to announce the commencement of a three
phase university study dedicated to creating an ideal music playlist to accompany therapeutic psychedelic
sessions. Previous research has established that music for a therapeutic psychedelic session can significantly
impact the experience.
Figure 1: NeonMind Developing Music Playlist for Psychedelic Therapy Sessions
To view an enhanced version of Figure 1, please visit:
https://orders.newsfilecorp.com/files/7646/79513_neonmi2.jpg
"The emotional arc of a musical playlist during a psychedelic session can play an important role in supporting
someone's therapeutic experience," says Rob Tessarolo, President & CEO of NeonMind. "Music can act as a
pathway that is followed throughout the patient's journey, taking them to places on an emotional level that they
wouldn't necessarily go without it. Working with Dr. Russo and his team means we're able to scientifically
investigate what have to date been assumptions about what makes a good playlist."
NeonMind is working with Dr. Frank Russo, a professor of Psychology at Ryerson University, who conducts
research on the biological, cognitive, and social-emotional bases of music and speech at the Science of Music
Auditory Research and Technology (SMART) Lab. He is also an affiliate scientist at the Toronto Rehabilitation
Institute, a core member of the McMaster Institute for Music and the Mind, and an adjunct professor at the
University of Toronto's Music and Health Collaboratory.
NeonMind will conduct the research in three phases:
an online playlist candidate validation study, surveying 50 people with relation to the self-transcendent
emotions experienced when listening to snippets of longer musical tracks;
an in-person playlist validation study at Ryerson's SMART Lab; and
a comprehensive in-person physiological validation study measuring biological markers to further
substantiate the potential for self-transcendent emotions that the playlist in question generates.
2/3
"This is an exciting frontier to be a part of that dovetails nicely with several aspects of research that I've been
conducting into the psychology of music throughout my career," says Dr. Russo. "Music without a psychedelic
has the potential to generate self-transcendent emotions such as compassion and awe, which may be
transformative; on the basis of past research on music and psychedelics, it seems that the music a person listens
to during a therapeutic trip is a major determinant of the overall experience. The playlist we are working towards
takes various theoretical considerations into account, and the series of studies we've designed will enable us to
iteratively assess and refine its efficacy."
Each phase will help the team assess and fine-tune the playlist which will then be used in NeonMind's clinical
trials and for the enhancement of psychedelic-assisted psychotherapy services.
About NeonMind Biosciences Inc.
NeonMind is engaged in research and development of products to optimize human health and performance.
NeonMind has two divisions, a pharmaceutical division engaged in drug development of psychedelic
compounds, and a consumer products division with a focus on mushroom infused products. NeonMind's
consumer division currently sells medicinal mushroom infused coffee products in Canada through NeonMind's
direct to consumer e-commerce platform. It also plans to launch medicinal dietary supplements in the U.S. this
spring.
In its pharmaceutical division, NeonMind has two distinct psilocybin drug development programs targeting
obesity. NeonMind's first drug candidate aims to use synthetic psilocybin to enhance a patient's ability to adopt
behaviours that cause weight loss and maintain that loss through psychedelic-assisted cognitive therapy. The
second drug candidate offers low dose synthetic psilocybin as a treatment to suppress appetite.
NeonMind's first drug candidate employs psilocybin as an agonist to the serotonin receptor 5- HT2A, which is
involved in the hallucinogenic effect of psychedelics, and the second drug candidate employs low-dose
psilocybin as an agonist to the 5-HT2C receptor, which controls appetite.
For more information on NeonMind, go to www.NeonMindBiosciences.com or buy NeonMind mushroom
infused coffee at www.NeonMind.com.
Rob Tessarolo, President & Chief Executive Officer, NeonMind Biosciences Inc.
Tel: 416-750-3101
Investor Relations:
Edge Communications
Tel: 1-866-318-6874
Renmark Financial Communications Inc.
Melanie Barbeau
mbarbeau@renmarkfinancial.com
Tel: 416-644-2020 or 212-812-7680
Media Inquiries:
Exvera Communications Inc.
The Canadian Securities Exchange has not reviewed, approved or disapproved the contents of this news release.
Cautionary Statement Regarding Forward-Looking Statements
3/3
Certain statements contained in this press release constitute forward-looking information. These statements
relate to future events or NeonMind's future performance. The use of any of the words "could", "expect",
"believe", "will", "projected","estimated" and similar expressions and statements relating to matters that are not
historical facts are intended to identify forward-looking information and are based on NeonMind's current belief
or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In
particular, NeonMind's drug development plans, its ability to retain key personnel, and its expectation as to the
development of its intellectual property and other steps in its preclinical and clinical drug development
constitute forward-looking information. Actual results and developments may differ materially from those
contemplated by forward-looking information. Readers are cautioned not to place undue reliance on forward-
looking information. The statements made in this press release are made as of the date hereof. NeonMind
disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a
result of new information, future events or otherwise, except as may be expressly required by applicable
securities laws.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/79513